No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AORT Artivion
- 19.940
- -0.370-1.82%
Close Apr 17 16:00 ET
- 19.940
- 0.0000.00%
Post 16:20 ET
831.69MMarket Cap-26586P/E (TTM)
20.640High19.940Low150.61KVolume20.410Open20.310Pre Close3.02MTurnover0.43%Turnover RatioLossP/E (Static)41.71MShares21.90052wk High2.95P/B692.30MFloat Cap12.15852wk Low--Dividend TTM34.72MShs Float42.745Historical High--Div YieldTTM3.45%Amplitude1.335Historical Low20.075Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
Needham Sees BSX, CNMD, RMD Beating Street, Despite Medtech Slow Down
Artivion Is Maintained at Buy by Needham
Artivion Is Maintained at Buy by Needham
Express News | Needham Maintains Buy on Artivion, Maintains $25 Price Target
Artivion Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 17.04% Needham $25 → $25 Maintains Buy 02/16/2024 3% Stifel $20 → $22 Maintains Buy 02/16/2024
Artivion's Growth Trajectory: A Buy Rating Amidst Promising Aortic Products and Financial Upswing
Comments
Artivion's management optimizes capital structure for a new phase of profitable growth. Strong conviction in business outlook, recent financial performance and clinical data readouts expected to deliver significant shareholder value.
Press Release: Artivion Obtains $350 Million in Senior Secured Credit FacilitiesArtivion's reinvestment has not significantly improved sales, resulting in a 52% decline in stock over the past five years. The market perspective shows skepticism, implying Artivion may not have substantial growth potential.
ColumnsToday's Pre-Market Stock Movers: QCOM, BA, ROKU, AZN and More
Gapping up
In reaction to earnings/guidance:
• $CalAmp(CAMP.US$ +0.6%
Other news:
• $Cano Health(CANO.US$ +6.1% ($Humana(HUM.US$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics(CORT.US$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial(LPLA.US$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona(XRAY.US$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN(VXX.US$ +2.9% (tr...
In reaction to earnings/guidance:
• $CalAmp(CAMP.US$ +0.6%
Other news:
• $Cano Health(CANO.US$ +6.1% ($Humana(HUM.US$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics(CORT.US$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial(LPLA.US$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona(XRAY.US$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN(VXX.US$ +2.9% (tr...
16
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg